Form 4: Tarsus Pharmaceuticals Director Wendy L. Yarno Acquires Shares
Insider Transaction Report
Director Wendy L. Yarno of Tarsus Pharmaceuticals, Inc. reported the acquisition of stock options and restricted stock units on June 25, 2026.
Summary
- Director Wendy L. Yarno acquired stock options and restricted stock units (RSUs) on June 25, 2026.
- The stock option grant is for 3,837 shares with an exercise price of $64.34, expiring on June 24, 2036.
- Additionally, Yarno received 2,417 RSUs that vest in full on the one-year anniversary of the grant date.
- A further grant of 1,209 RSUs was also received, with vesting in installments on September 15, 2026, December 15, 2026, March 15, 2027, and June 15, 2027.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard equity grant to a director and does not provide new financial information or strategic updates.
Positives
- Director Wendy L. Yarno has acquired equity in the company, indicating confidence in its future.
- The acquisition includes both stock options and restricted stock units, providing multiple avenues for potential value realization.
- Vesting schedules for RSUs are staggered, aligning with continued service and potentially incentivizing long-term commitment.
Risks
- The value of stock options is contingent on the stock price exceeding the exercise price of $64.34.
- Vesting of equity awards is subject to the reporting person's continuous service with the company.
Future Outlook
The filing does not contain forward-looking statements or guidance. It solely reports on a transaction by a director.
Industry Context
StockSavvy.ai notes that the issuance of stock options and RSUs to directors is a common practice in the pharmaceutical industry to align executive and director interests with shareholder value and to attract and retain talent.
Stakeholder Impact
- Shareholders: The grant of equity awards to directors is a standard compensation practice. The ultimate impact on shareholders will depend on the company's future performance and stock price appreciation.
Key Dates
| Date | Description |
|---|---|
| 06/25/2026 | Date of earliest transaction and grant of stock options and RSUs. |
| 09/15/2026 | First vesting date for a portion of the RSUs. |
| 12/15/2026 | Second vesting date for a portion of the RSUs. |
| 03/15/2027 | Third vesting date for a portion of the RSUs. |
| 06/15/2027 | Fourth and final vesting date for a portion of the RSUs. |
| 06/24/2036 | Expiration date of the granted stock options. |
Keywords
Tarsus Pharmaceuticals, Form 4, Insider Trading, Stock Options, Restricted Stock Units, Director Compensation, SEC Filing, Equity Awards
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.